Retrospective, cross-sectional study of patients with lower limb (excluding foot and ankle) sarcoma (LSS ; Amp ) Mean age at assessment = 35 (14–76) years Mean time from surgery = 46 (6–250) months
Retrospective comparative study on patients with sarcoma of the lower limb with at least 2-year followup (Amp , LSS ) Mean age at surgery = 40.36 (2–86) years Mean time from treatment = 8.91 (2–27) years.
Retrospective cross-sectional study on survivors of locally advanced, nonmetastatic STS, who underwent isolated limb perfusion, with intentional delayed LSS (LSS , Amp ) Median age at perfusion = 49 (14–72) years Median time since perfusion = 7 (1–13) years
IES SF-36 Perception of involvement in decision Treatment satisfaction: 5-point Likert scale
Retrospective cohort study on adult patients with nonmetastatic extremity STS who underwent LSS Outcome measures assessed at two time points: preoperatively and 12 months postoperatively Categories collapsed to allow for sufficient powering
Outcome expectation questionnaire MSTS87 TESS RNL EQ5D-VAS LOT
Cross-sectional descriptive study on sarcoma patients in different phases of disease
Dx , mean time from diagnosis = 4.27 months; Rx , mean time from diagnosis = 10.94 months, mean time from treatment = 9.34 months; Fx , mean time since completion of treatment = 52.93 months MAD = 48.32 years
HADS Demographic and clinical questionnaire
STS: soft tissue sarcoma; PreRT: neoadjuvant radiation therapy; PostRT: adjuvant radiation therapy; MAD: mean age of diagnosis; Amp: amputation; LSS: limb sparing surgery; Dx: diagnosis phase; Rx: treatment phase (1st treatment, whether it was chemotherapy, radiation therapy, and/or surgery counted as index timepoint); Fx: followup phase.